➡
upstream target
Amyloid-Beta oligomers as upstream initiator of AD cascade
➡ Upstream Target
alzheimer
Identification:
MR+RCT+KO
✗ KILL CRITERIA
Aβ removal does not improve cognition in Phase 3 trials
Aβ is downstream of other initiating events (not upstream)
Anti-Aβ antibodies fail to slow disease progression
Convergence
4
Evidence Count
6
Falsification Wt
0.45
Effect Size
3.1
View on SciDEX ↗